Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its upcoming dividend payout. For more information, check out Everything Investors Need to Know About Ex-Dividend Dates.
Below we highlight 10 big-name stocks going ex-dividend for the week of March 10-14.
1. AltriaAltria Group (MO) is set to trade ex-dividend on March 12. The tobacco company offers a dividend yield of 5.20% based on Wednesday�� closing price of $36.95 and the company�� quarterly dividend payout of 48 cents. The stock is down 3% year-to-date. Dividend.com currently rates MO as “Recommended” with a DARS��rating of 3.5 stars out of 5 stars.
Top Stocks To Own Right Now: Affymax Inc.(AFFY)
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.
Advisors' Opinion:- [By Kanak Kanti De]
Amgen needed an Onyx-like acquisition badly. For one, sales of Aranesp and Epogen, its flagship drugs for anemia, are dropping on concerns of safety, and loss of monopoly in 2012 to Affymax (AFFY), which received FDA approval for a rival anemia drug. (Note though, that after Omontys was recalled this year, that problem is resolved for Amgen.) Secondly, four of its top selling products go off patent in 2015.
Top 5 Up And Coming Companies For 2014: Jazz Pharmaceuticals Inc.(JAZZ)
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company markets Xyrem, a sodium oxybate oral solution for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder. Its product candidates under clinical development include JZP-6, a Phase III pivotal clinical trials completed product for the treatment of fibromyalgia; and JZP-8, an intranasal formulation of clonazepam, which has completed Phase II clinical trial for the treatment of acute repetitive seizures in epilepsy and solid oral dosage forms of sodium oxybate. The company sells its products through specialty sales force targeting sleep specialists, psychiatrists, neurologists, and pulmonologists. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headq uartered in Palo Alto, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Shares of Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) got a boost, shooting up 7.77 percent to $123.65 after the company announced its plans to buy Gentium SpA (NASDAQ: GENT) for around $1 billion.
- [By Selena Maranjian]
For example, consider Lone Pine Capital, founded by Steve Mandel�in 1997. Lone Pine is one of the biggest hedge fund companies, and it has reportedly outperformed�the S&P 500 handily since inception. Its reportable stock portfolio totaled $23 billion�in value as of March 31, 2014. According to its recently released 13F statement, Lone Pine established or added to positions in Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) , SouFun Holdings Ltd (NYSE: SFUN ) , and Valeant Pharmaceuticals International (NYSE: VRX ) .
Top 5 Up And Coming Companies For 2014: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi. - [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
Top 5 Up And Coming Companies For 2014: Heidrick & Struggles International Inc (HSII)
Heidrick & Struggles International, Inc. (Heidrick & Struggles) is an advisory firm providing executive search and leadership consulting services. As of December 31, 2011, the Company provided its services to a range of clients through the expertise of 347 consultants located in various cities around the world. The Company�� service offerings include executive search, leadership consulting and client base. The Company helps its clients build leadership teams by facilitating the recruitment, management and deployment of senior executives. In addition to executive search, it provides a range of leadership consulting services to clients. These services include succession planning, executive assessment, talent retention management, executive development, transition consulting for newly appointed executives, and mergers and acquisitions human capital integration consulting. In November 2013, Heidrick & Struggles International, Inc announced the acquisition of Scambler MacGregor.
The Company�� clients includes clients include Fortune 1000 companies, non-United States companies, middle market and emerging growth companies, governmental, higher education and not-for-profit organizations and other private and public entities. Heidrick & Struggles provides senior-level executive search and leadership consulting services to its clients worldwide through a network of more than 69 offices in 40 countries. The locations are staffed with consultants, research associates, administrative assistants and other support staff. Administrative functions are centralized where possible, although certain support and research functions are situated regionally because of variations in local requirements.
The Company�� worldwide network includes affiliate relationships in Finland, South Africa, Turkey and Portugal. It has no financial investment in these affiliates but receive licensing fees from them for the use of its name and its databases. Licensing fees are less than 1% of its net revenue. As ! of December 31, 2011, the Company had 160 consultants in its Americas segment, which included New York, Chicago and Atlanta. As of December 31, 2011, the Company had 104 consultants in its European segment, which included the United Kingdom, Germany and France. As of December 31, 2011, the Company had 83 consultants in itsAsia Pacific segment, which included China (including Hong Kong), Australia and Singapore. The Company�� executive search business operates in six broad industry groups: Financial Services, Industrial, Consumer Markets, Global Technology and Services, Life Sciences, and Education and Social Enterprise.
Its executive search consultants also specialize in searches for specific C-level functional positions, which are roles that generally report directly to the chief executive officer. These include chief financial officers, chief information officers, chief legal officers, chief marketing officers and chief human resources officers. The Company�� Global Functional Practices include Chief Executive Officer and Board of Directors; Chief Human Resources Officers; Financial Officers; Information Officers; Interim Executives; Legal, Risk, Compliance & Government Affairs; Marketing, Sales & Strategy Officers; Multicultural & Digital Marketing; Sales Officers; Research & Development; and Supply Chain & Transportation.
The Company competes with Egon Zehnder International, Korn/Ferry International, Russell Reynolds Associates, Inc. and Spencer Stuart & Associates.
Advisors' Opinion:- [By Rich Smith]
Chicago-based Heidrick & Struggles (NASDAQ: HSII ) needs a new CEO.
For weeks, rumors have swirled that Heidrick was on the block for possible sale to a new owner. Those rumors were squashed Monday, however, when the executive-search firm simultaneously announced that (a) it has decided to pursue a "stand-alone strategy," and (b) that Chief Executive Officer L. Kevin Kelly is leaving the company. (The company also had some good news -- revenues for the fiscal second quarter look to be close to the high point of its previously announced $110 million-to-$120 million range.)
- [By Anders Bylund]
And if you thought this crack team would look only at internal promotion candidates, headhunter firm Heidrick & Struggles (NASDAQ: HSII ) is there to vet the field of outsider candidates. It's a high-profile contract for Heidrick, but the stock fell 0.7% today anyhow. The lack of popping champagne corks in the company's Chicago headquarters is an indication of just how tough this recruitment drive will be.
- [By GuruFocus]
Heidrick & Struggles International Inc. (HSII): Interim CEO Jory J. Marino Bought 9,917 Shares
Interim CEO of Heidrick & Struggles International Inc. (HSII) Jory J. Marino bought 9,917 shares on 08/23/2013 at an average price of $15.03. Heidrick & Struggles International Inc. was formed as a Delaware corporation in 1999. Heidrick & Struggles International Inc. has a market cap of $272.497 million; its shares were traded at around $15.03 with a P/E ratio of 61.73 and P/S ratio of 0.58. The dividend yield of Heidrick & Struggles International Inc. stocks is 3.46%.
No comments:
Post a Comment